Albireo Selling General and Administrative Expense from 2010 to 2023

Delisted . USA . 
Stock . Albireo Pharma
ALBODelisted Stock  USD 44.15  0.75  1.67%   
Albireo Pharma Selling General and Administrative Expense yearly trend continues to be very stable with very little volatility. Selling General and Administrative Expense is likely to grow to about 86.3 M this year. During the period from 2010 to 2023, Albireo Pharma Selling General and Administrative Expense quarterly data regression pattern had range of 81,858,483 and median of  15,786,000. Albireo Pharma Weighted Average Shares is very stable at the moment as compared to the past year. Albireo Pharma reported last year Weighted Average Shares of 22.1 Million. As of 21st of March 2023, Weighted Average Shares Diluted is likely to grow to about 23.8 M, while Consolidated Income is likely to drop (33 M).
  
Check Albireo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Albireo main balance sheet or income statement drivers, such as Direct Expenses of 1.2 M, Cost of Revenue of 1.2 M or Gross Profit of 48.7 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0502, PPandE Turnover of 67.56 or Receivables Turnover of 6.79. Albireo financial statements analysis is a perfect complement when working with Albireo Pharma Valuation or Volatility modules. It can also supplement various Albireo Pharma Technical models . Please continue to Trending Equities.

Albireo Selling General and Administrative Expense Breakdown

Showing smoothed Selling General and Administrative Expense of Albireo Pharma with missing and latest data points interpolated. A component of Operating Expenses representing the aggregate total costs related to selling a firm's product and services; as well as all other general and administrative expenses. Direct selling expenses (for example; credit; warranty; and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products; for example telephone expenses; Internet; and postal charges. General and administrative expenses include salaries of non-sales personnel; rent; utilities; communication; etc.Albireo Pharma's Selling General and Administrative Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Albireo Pharma's overall financial position and show how it may be relating to other accounts over time.
Selling General and Administrative Expense10 Years Trend
Up
Slightly volatile
Compare to OthersAll Fundamentals
   Selling General and Administrative Expense   
       Timeline  

Albireo Selling General and Administrative Expense Regression Statistics

Arithmetic Mean27,564,774
Geometric Mean16,085,601
Coefficient Of Variation107.47
Mean Deviation24,011,820
Median15,786,000
Standard Deviation29,624,980
Range81,858,483
R-Value0.87
R-Squared0.75
Significance0.00006447
Slope6,126,884

Albireo Selling General and Administrative Expense History

202386.3 M
202280 M
202169.6 M
202042.4 M
201923 M
201818.1 M
201715.2 M
201615.8 M
20144.5 M
20135.6 M
20126.8 M

About Albireo Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Albireo Pharma income statement, its balance sheet, and the statement of cash flows. Albireo Pharma investors use historical funamental indicators, such as Albireo Pharma's Selling General and Administrative Expense, to determine how well the company is positioned to perform in the future. Although Albireo Pharma investors may use each financial statement separately, they are all related. The changes in Albireo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Albireo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Albireo Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Albireo Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2023
Selling General and Administrative Expense80 M86.3 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Watchlist Optimization Now

   

Watchlist Optimization

Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
All  Next Launch Module
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY